# US 2016/0257956 A1 · Interfering rna delivery system and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257956 A1
- Document ID: US20160257956A1
- Status: Published application
- Kind: A1
- Application number: 15/132,712
- Filed: 2016-04-19
- Published: 2016-09-08
- Earliest claimed: 2012-01-06
- Assignees: Arrowhead Pharmaceuticals, Inc.
- Applicants: Arrowhead Pharmaceuticals Inc.
- Inventors: Ying Yu; Jon E. Chatterton
- Web page: https://patentgrep.com/patent/US20160257956A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- A61K 48/0033: {the non-active part being non-polymeric}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/3513: Protein; Peptide
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12Y 502/01008: Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.

## Claims

### Claim 1

An composition comprising an interfering RNA molecule covalently linked to a YM3-10H peptide, wherein the YM3-10H peptide comprises a peptide contains the amino acid sequence of SEQ ID NO: 1 and at least ten histidine residues.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the YM3-10H peptide contains at least five amino-terminal histidine residues and at least five carboxy-terminal histidine residues.

### Claim 3 (depends on 1)

The composition of claim 1 wherein the YM3-10H peptide contains at least ten amino-terminal histidine residues.

### Claim 4 (depends on 1)

The composition of claim 1 wherein the YM3-10H peptide contains at least ten carboxy-terminal histidine residues.

### Claim 5 (depends on 1)

The composition of claim 1 wherein the YM3-10H peptide contains an amino-terminal cysteine residue.

### Claim 6 (depends on 1)

The composition of claim 1 wherein the YM3-10H peptide contains a carboxy-terminal cysteine residue.

### Claim 7 (depends on 1)

The composition of claim 1 wherein the YM3-10H peptide contains an amino-terminal cysteine residue and a carboxy-terminal cysteine residue.

### Claim 8 (depends on 1)

The composition of claim 1 wherein the composition further contains a second YM3-10H peptide, wherein the YM3-10H peptide and second YM3-10H peptide form a concatemer.

### Claim 9

The composition of, wherein the YM3-10H peptide comprises:
(SEQ ID NO: 2)
CHHHHHTHRLPRRRRRRHHHHHC;
(SEQ ID NO: 3)
HHHHHTHRLPRRRRRRHHHHHC;
(SEQ ID NO: 4)
THRLPRRRRRRHHHHHHHHHHC;
(SEQ ID NO: 5)
GGTHRLPRRRRRRHHHHHHHHHHC;
(SEQ ID NO: 6)
THRLPRRRRRRGGHHHHHHHHHHC;
(SEQ ID NO: 7)
THRLPRRRRRRHHHHHGGHHHHHC;
(SEQ ID NO: 8)
THRLPRRRRRRHHHHHHHHHHC;
or
(SEQ ID NO: 9)
CTHRLPRRRRRRHHHHHHHHHHC.

### Claim 10 (depends on 1)

The composition of claim 1 wherein the interfering RNA molecule is covalently linked to the YM3-10H peptide via a spacer.

### Claim 11 (depends on 10)

The composition of claim 10 wherein the concatemer comprises the amino acid sequence of SEQ ID NO. 10.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the interfering RNA molecule is a siRNA, miRNA, or shRNA.

### Claim 13

A pharmaceutical composition comprising an interfering RNA molecule covalently linked to a YM3-10H peptide, wherein the YM3-10H peptide comprises a peptide contains the amino acid sequence of SEQ ID NO: 1 and at least ten histidine residues and a pharmaceutically acceptable carrier.

### Claim 14

A method of delivering an interfering RNA molecule into a cell, comprising:
(a) covalently linking an interfering RNA molecule to a YM3-10H peptide wherein the YM3-10H peptide comprises a peptide contains the amino acid sequence of SEQ ID NO: 1 and at least ten histidine residues; and
(b) administering the interfering RNA delivery system to the cell.

### Claim 15 (depends on 14)

The method of claim 14, wherein the interfering RNA molecule is a siRNA, miRNA, or shRNA.

### Claim 16 (depends on 14)

The method of claim 14, wherein the YM3-10H peptide comprises:
(SEQ ID NO: 2)
CHHHHHTHRLPRRRRRRHHHHHC;
(SEQ ID NO: 3)
HHHHHTHRLPRRRRRRHHHHHC;
(SEQ ID NO: 4)
THRLPRRRRRRHHHHHHHHHHC;
(SEQ ID NO: 5)
GGTHRLPRRRRRRHHHHHHHHHHC;
(SEQ ID NO: 6)
THRLPRRRRRRGGHHHHHHHHHHC;
(SEQ ID NO: 7)
THRLPRRRRRRHHHHHGGHHHHHC;
(SEQ ID NO: 8)
THRLPRRRRRRHHHHHHHHHHC;
or
(SEQ ID NO: 9)
CTHRLPRRRRRRHHHHHHHHHHC.
